TABLE 2.

Association of circulating galectin-3 with graft failure in 561 kidney transplant recipients

Models	Galectin-3
	Tertile 1	Tertile 2	Tertile 3	Ln, per 1 SD
	Ref.	HR (95% CI)	HR (95% CI)	HR (95% CI)	P
Unadjusted	1.00	1.51 (0.72-3.16)	4.97 (2.62-9.45)	2.11 (1.71-2.61)	<0.001
Model 1	1.00	1.22 (0.58-2.58)	2.90 (1.44-5.85)	1.77 (1.38-2.27)	<0.001
Model 2	1.00	1.53 (0.71-3.27)	4.07 (1.96-8.48)	2.12 (1.63-2.75)	<0.001
Model 3	1.00	1.28 (0.59-2.78)	3.30 (1.56-6.98)	2.07 (1.56-2.75)	<0.001
Model 4	1.00	1.50 (0.70-3.23)	3.79 (1.81-7.95)	2.06 (1.58-2.69)	<0.001
Model 5	1.00	1.48 (0.69-3.17)	3.73 (1.76-7.91)	2.13 (1.60-2.48)	<0.001
Model 6	1.00	1.60 (0.75-3.44)	3.77 (1.79-7.96)	1.97 (1.50-2.58)	<0.001

Cox proportional-hazards regression analyses were performed to assess the association of galectin-3 with graft failure (n = 72). Multivariable model 1 was adjusted for eGFR. Model 2 was adjusted for eGFR, donor age, recipient age, body mass index, dialysis vintage, type of transplant, and time since transplantation. In each following model, adjustments were performed additive to adjustments performed in model 2. These included adjustment for immunosuppressive therapy, circulating anti-HLA class I antibodies, circulating anti-HLA class II antibodies, and inflammatory parameters (acute rejection treatment, use of proliferator inhibitor, high-sensitivity C-reactive protein, and soluble vascular cell adhesion molecule 1) in model 3; diabetes and glucose homeostasis (history of diabetes, glycated hemoglobin, and homeostasis model assessment of insulin resistance) in model 4; traditional cardiovascular risk factors (systolic blood pressure, use of antihypertensive medication, smoking status, triglycerides, high-density lipoprotein cholesterol) in model 5; and, N-terminal pro b-type natriuretic peptide and high-sensitive troponin T in model 6.

CI, confidence intervals; eGFR, estimated glomerular filtration rate; HR, hazard ratios.